Literature DB >> 28522069

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary.

Yuan Yu Michael Huang1, Sylvia Hsu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28522069     DOI： 10.1016/j.jaad.2017.02.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.

Authors:  A B Kimball; K A Papp; K Reich; M Gooderham; Q Li; N Cichanowitz; C La Rosa; A Blauvelt
Journal:  Br J Dermatol       Date:  2019-11-19       Impact factor: 9.302
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.